HOME
SEARCH
RSS FEED
SUBSCRIBE
Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease
Case ID:
TAB-778
Web Published:
12/6/2022
Description:
Tumor Necrosis Factor alpha (TNF-alpha) is a multifunctional cytokine that mediates inflammation, immune regulation, and cellular proliferation. This cytokine is converted to its active form by TNF-alpha converting enzyme (TACE). Pathological increases in TNF-alpha activity have been associated with a wide variety of inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer. Inhibiting the conversion of TNF-alpha to its active form by inhibiting TACE represents a potential treatment for these diseases.
The current technology provides peptides, derived from an N-terminal fragment of the TACE protein, that inhibit TACE activity. Also described are methods of using these peptides to lower levels of active TNF-alpha. These peptides could be used as a treatment for TNF-alpha-mediated inflammatory diseases.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Peptides_for_Treatment_of_Tumor_Necr osis_Factor_alpha_Mediated_Inflammatory_Disease
Category(s):
Licensing
Research Materials
Diagnostics
Therapeutics
Immunology
Bookmark this page
Download as PDF
For Information, Contact:
Michael Shmilovich
Senior Licensing And Patenting Manager
NIH Technology Transfer
301-435-5019
shmilovm@nih.gov
Inventors:
Stewart Levine
Keywords:
Crohn disease
Demyelinating diseases
IB3XXX
IBXXXX
Inflammatory bowel disease 1
IXXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum